Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Hematology. American Society of Hematology. Education Program|December 4, 2020
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitorsAshley Hanlon, Danielle M BranderPatient Preference and Adherence|April 27, 2012
Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibDanielle M Brander, Anne W BeavenBlood Advances|April 29, 2020
Impact of exercise on the immune system and outcomes in hematologic malignanciesAndrea Sitlinger, Danielle M Brander, David B BartlettCancer Biology & Therapy|March 28, 2018
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapiesAnthony R Mato, Jennifer C Samp, Geneviève Gauthier, et al.Scientific Reports|December 1, 2021
A pilot study of high-intensity interval training in older adults with treatment naïve chronic lymphocytic leukemiaGrace MacDonald, Andrea Sitlinger, Michael A Deal, et al.Journal of Geriatric Oncology|September 12, 2022
Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot studyAshley L Artese, Andrea Sitlinger, Grace MacDonald, et al.Blood Advances|January 26, 2026
An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLLMazyar Shadman, Constantine S Tam, Danielle M Brander, et al.British Journal of Haematology|November 17, 2018
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemiaDanielle M Brander, Daphne R Friedman, Alicia D Volkheimer, et al.Cells|June 2, 2021
Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)Andrea Sitlinger, Michael A Deal, Erwin Garcia, et al.Leukemia & Lymphoma|July 19, 2013
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studiesDaphne R Friedman, Mark C Lanasa, Patricia H Davis, et al.Pageof 5